Insilico to use IPO funds to scale up AI drug discovery, says CEO

Alex Zhavoronkov, Founder and CEO of generative-AI drug discovery firm Insilico Medicine, discusses the company's plans after it raised $293 million in its initial public offering in Hong Kong. He talks about using artificial intelligence in early-stage drug discovery, longevity therapeutics, and how Insilico's AI model can simulate different life stages.